- 13.8% consolidated service revenue
growth - Integrated Healthcare Services segment grew service
revenues by 32.6% compared to the third quarter of 2013
- Consolidated book-to-bill ratio of 1.42
results from 12.8% growth in net new business compared to the third
quarter of 2013
- Third quarter diluted adjusted EPS
increased 22.6% to $0.65 per share compared to the third quarter of
2013
- Third quarter GAAP reported diluted EPS
increased 42.0% to $0.71 per share compared to the third quarter of
2013
- Adjusted full year 2014 service revenue
guidance of $4.16 billion - $4.19 billion and increased diluted
adjusted EPS guidance to $2.61 - $2.68 per share, representing
diluted adjusted EPS growth of 26.7% to 30.1% compared to full year
2013
Quintiles Transnational Holdings Inc. (“Quintiles” or the
“Company”) (NYSE: Q) today reported its financial results for the
third quarter ended September 30, 2014.
For the three months ended September 30, 2014, the Company’s
service revenues were $1.06 billion which represents growth of
13.8%, or $128.3 million compared to the same period last year at
actual foreign exchange rates. The Company’s growth in service
revenues, excluding the impact of foreign currency fluctuations
(“constant currency”), was 14.0% with 7.9% growth in the Product
Development segment and 33.9% growth in the Integrated Healthcare
Services segment.
Adjusted income from operations was $150.9 million in the third
quarter of 2014, representing growth of 13.9% compared to the same
period last year. The adjusted income from operations margin was
14.2%, which is consistent with the same period last year. Adjusted
net income was $85.0 million in the third quarter of 2014,
representing growth of 20.2% compared to the same period last year.
Diluted adjusted earnings per share was $0.65 in the quarter ended
September 30, 2014, representing growth of 22.6% compared to the
same period last year.
Reported GAAP income from operations was $149.1 million,
reported GAAP net income was $92.7 million and reported GAAP
diluted earnings per share was $0.71 for the three months ended
September 30, 2014. Reconciliations of the non-GAAP measures,
including adjusted income from operations, adjusted net income and
diluted adjusted earnings per share to the corresponding GAAP
measures are attached to this press release.
Net new business grew 12.8% compared to the same period last
year to $1.51 billion representing a book-to-bill ratio of 1.42 in
the quarter ended September 30, 2014. This net new business
contributed to an ending backlog of $10.75 billion at September 30,
2014.
“Quintiles is a story of consistent performance with a focus on
industry leadership, and I am proud to report that this story
continued in the third quarter of 2014,” said Chief Executive
Officer Tom Pike. “For the third quarter, our consolidated revenue
increased by 13.8% compared to the same period last year.”
“Further, I am pleased to report that net new business,
revenues, and EPS for the third-quarter grew at double-digit
rates,” Pike said. “We finished the quarter with revenue growth of
32.6% in our IHS segment, showcasing significant progress. The
third quarter net new business allowed Quintiles to keep its
industry-leading backlog of $10.75 billion. Our strong
performance continues to strengthen our platform which allows us to
capitalize on strategic priorities and create value for our
customers and investors,” Pike explained.
The Product Development segment net new business totaled $1.27
billion in the quarter ended September 30, 2014 which translates to
a book-to-bill ratio of 1.64. The net new business increased 47%
compared to the same period in 2013, led by the five-year renewal
of a significant contract in our clinical and data management
functional resourcing services businesses. Product Development’s
service revenues grew 8.0% compared to the same period last year to
$771.4 million at actual foreign exchange rates. At constant
currency exchange rates, Product Development’s service revenues
grew 7.9%, or $56.3 million during the third quarter of 2014
compared to the same period last year. The service revenue growth
resulted from volume-related increases in global laboratory
services, clinical trial support services, services provided on a
functional resource basis and from the Novella acquisition in 2013,
partially offset by the conclusion of a large clinical solutions
project which was delivered throughout 2013. Product Development’s
income from operations margin was 20.5% for the third quarter,
representing an improvement of 80 basis points compared to the same
period last year, including 30 basis points from favorable currency
fluctuations.
The Integrated Healthcare Services segment net new business
totaled $244 million which translates to a book-to-bill ratio of
.84 for the quarter ended September 30, 2014. At actual foreign
exchange rates, Integrated Healthcare Services’ service revenues
increased 32.6%, or $71.1 million, during the third quarter of 2014
compared to the same period last year to $289.6 million including
$19.2 million from the Encore acquisition, partially offset by $2.8
million of unfavorable foreign currency impacts. On a constant
currency basis, Integrated Healthcare Services’ service revenues
increased 33.9% during the third quarter of 2014 compared to the
same period last year, primarily due to increases in commercial
solutions in Japan and North America as well as growth in
real-world and late phase research services partially offset by a
decline in commercial solutions in Europe. Integrated Healthcare
Services’ income from operations margin was 6.9% for the third
quarter, representing an improvement of 160 basis points compared
to the same period last year, including unfavorable currency
fluctuations of 30 basis points.
General corporate and unallocated expenses were $27.2 million
during the quarter ended September 30, 2014 compared to $19.8
million for the same period last year.
Interest expense was $25.1 million during the quarter ended
September 30, 2014 compared to $28.8 million for the same period
last year. Interest expense was lower than the same period in 2013
due to a decrease in the average rate of interest.
Other income, net was $7.8 million during the quarter ended
September 30, 2014 compared to $3.2 million of net expenses for the
same period last year. Other income, net was higher than the same
period in 2013 due to a change in fair value of contingent
consideration payable for an acquisition, partially offset by other
expenses.
The GAAP effective income tax rate was 31.1% for the quarter
ended September 30, 2014 compared to 29.1% for the same period in
2013 as a higher percentage of income was delivered in the United
States during the current period compared to the same period last
year.
For the nine months ended September 30, 2014, the Company’s
constant currency service revenue growth was 10.3%, or $289.7
million as compared to the same period in 2013. At actual foreign
exchange rates, the Company’s service revenues of $3.1 billion for
the nine months ended September 30, 2014, grew 10.6% compared to
the same period in 2013 which included a positive foreign currency
impact of $7.7 million. Adjusted income from operations for the
nine months ended September 30, 2014 was $435.2 million
representing growth of 16.1% compared to the same period in 2013.
Adjusted income from operations margin was 14.0% representing 60
basis points of margin expansion compared to the same period last
year of which 50 basis points was from favorable currency
fluctuations. Adjusted net income was $261.6 million for the nine
months ended September 30, 2014 representing growth of 36.9%
compared to the same period last year. Diluted adjusted earnings
per share was $1.98 for the nine months ended September 30, 2014
representing growth of 31.1% compared to the same period last year.
Reported GAAP income from operations was $431.5 million, reported
GAAP net income was $268.0 million and reported GAAP diluted
earnings per share was $2.03 for the nine months ended September
30, 2014.
Financial Guidance
Prior guidance was based on foreign currency exchange rates at
June 30, 2014. Because of significant changes in foreign currency
exchange rates occurring after that date, 2014 service revenues are
estimated to be approximately $40.0 million less than prior
guidance, of which the third quarter was negatively impacted by
approximately $10.0 million. The Company has adjusted its full year
2014 guidance, which includes service revenues estimated to be
between $4.16 billion and $4.19 billion, representing growth of
9.2% to 10.0% compared to 2013, and raised diluted adjusted
earnings per share to $2.61 to $2.68 per share representing growth
of 26.7% to 30.1% compared to 2013, with diluted GAAP earnings per
share between $2.61 and $2.68 per share. The annual effective
income tax rate is estimated to be approximately 30%. This
financial guidance is based on the actual results for the nine
month period ended September 30, 2014 combined with our estimates
for the remaining three months of 2014, assuming the foreign
currency exchange rates at September 30, 2014 stay in effect for
the remainder of the year, and does not reflect the impact of any
future equity repurchases.
During the third quarter of 2014, the Company began excluding
changes from adjustments to estimated contingent consideration from
business combinations from adjusted net income and diluted adjusted
earnings per share. All periods presented in the tables
accompanying this press release have been adjusted to reflect this
change.
Webcast & Conference Call Details
Quintiles will host a conference call at 8:00 a.m. EDT today to
discuss its third quarter 2014 financial results. To participate,
please dial +1 (855) 484-7367 or +1 (631) 259-7541 outside the
United States approximately 15 minutes before the scheduled start
of the call. The conference call will also be accessible, live via
webcast, on the Investors section of the Quintiles website at
www.quintiles.com/investors. An archived replay of the conference
call will be available online at www.quintiles.com/investors after
1:00 p.m. EDT today.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000
employees conducting business in approximately 100 countries, we
helped develop or commercialize all of 2013’s top-100 best-selling
drugs on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit
www.quintiles.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements reflect, among other
things, the Company’s current expectations and anticipated results
of operations, all of which are subject to known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements, market trends or industry results to
differ materially from those expressed or implied by such
forward-looking statements. Therefore, any statements contained
herein that are not statements of historical fact may be
forward-looking statements and should be evaluated as such. Without
limiting the foregoing, the words “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“should,” “guidance,” “targets,” “will” and the negative thereof
and similar words and expressions are intended to identify
forward-looking statements. Actual results may differ materially
from the Company’s expectations due to a number of factors,
including that most of the Company’s contracts may be terminated on
short notice, and that the Company may be unable to maintain large
customer contracts or to enter into new contracts; the Company may
under-price its contracts, overrun its cost estimates, or fail to
receive approval for or experience delays in documenting change
orders; the historical indications of the relationship of backlog
to revenues may not be indicative of their future relationship; the
Company may be unable to maintain information systems or
effectively update them; customer or therapeutic concentration
could harm the Company’s business; the Company’s business is
subject to risks associated with international operations,
including economic, political and other risks such as compliance
with a myriad of laws and regulations, complications from
conducting clinical trials in multiple countries simultaneously and
changes in exchange rates; the market for the Company’s services
may not grow as the Company expects; government regulators or
customers may limit the scope of prescription or withdraw products
from the market, and government regulators may impose new
regulatory requirements or may adopt new regulations affecting the
biopharmaceutical industry; the Company may be unable to
successfully develop and market new services or enter new markets;
the Company’s failure to perform services in accordance with
contractual requirements, regulatory standards and ethical
considerations may subject it to significant costs or liability,
damage its reputation and cause it to lose existing business or not
receive new business; the Company’s services are related to
treatment of human patients, and it could face liability if a
patient is harmed; the Company’s effective income tax rate may
fluctuate, which may adversely affect our operations, earnings and
earnings per share; the Company may be unable to successfully
identify, acquire and integrate businesses, services and
technologies; and the Company has substantial indebtedness and may
incur additional indebtedness in the future, which could adversely
affect the Company’s financial condition. For a further discussion
of the risks relating to the Company’s business, see the “Risk
Factors” in Quintiles’ annual report on Form 10-K for the fiscal
year ended December 31, 2013, filed with the SEC on February 13,
2014, as such factors may be amended or updated from time to time
in Quintiles’ periodic filings with the SEC, which are accessible
on the SEC's website at www.sec.gov. These factors should not be
construed as exhaustive and should be read in conjunction with the
other cautionary statements that are included in this release and
in Quintiles’ filings with the SEC. The Company assumes no
obligation to update any such forward-looking statement after the
date of this release, whether as a result of new information,
future developments or otherwise.
Use of Non-GAAP Financial Measures
This press release includes adjusted EBITDA, adjusted income
from operations, adjusted income from operations margin, adjusted
net income and diluted adjusted earnings per share, each of which
is a financial measure not prepared in accordance with accounting
principles generally accepted in the United States (“GAAP”).
Management believes that these non-GAAP measures provide useful
supplemental information to management and investors regarding the
underlying performance of the Company’s business operations and are
more indicative of core operating results as they exclude certain
items whose fluctuations from period-to-period do not necessarily
correspond to changes in the core operations of the
business. These non-GAAP measures are performance measures
only and are not measures of the Company’s cash flows or liquidity,
nor are they alternatives for measures of financial performance
prepared in accordance with GAAP and may be different from
similarly titled non-GAAP measures used by other companies.
Investors and potential investors are encouraged to review the
reconciliations of the non-GAAP financial measures to their most
directly comparable GAAP measures attached to this press
release.
Internet Posting of Information: The Company routinely posts
information that may be important to investors in the 'Investors'
section of the Company’s website at www.Quintiles.com. The Company
encourages investors and potential investors to consult the
Company’s website regularly for important information about the
Company.
Click here to subscribe to Mobile Alerts for Quintiles.
QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands,
except per share data) (unaudited)
Three Months Ended September 30, Nine Months Ended
September 30, 2014 2013 2014 2013
Service revenues $ 1,061,013 $ 932,727 $ 3,101,777 $
2,804,400 Reimbursed expenses 339,021 263,112
947,133 915,960 Total revenues
1,400,034 1,195,839 4,048,910 3,720,360 Costs of revenue, service
costs 691,051 600,694 2,009,287 1,829,469 Costs of revenue,
reimbursed expenses 339,021 263,112 947,133 915,960 Selling,
general and administrative 219,027 199,573 657,283 627,713
Restructuring costs 1,793 7,201
3,749 11,897 Income from operations 149,142
125,259 431,458 335,321 Interest income (602 ) (1,119 ) (2,851 )
(2,356 ) Interest expense 25,050 28,756 74,552 96,682 Loss on
extinguishment of debt — — — 16,543 Other (income) expense, net
(7,776 ) 3,224 (9,564 ) 1,378
Income before income taxes and equity in earnings (losses)
of unconsolidated affiliates 132,470 94,398 369,321 223,074 Income
tax expense 41,260 27,459
111,049 68,407 Income before equity in
earnings (losses) of unconsolidated affiliates 91,210 66,939
258,272 154,667 Equity in earnings (losses) of unconsolidated
affiliates 1,523 (355 ) 9,785
(1,574 ) Net income 92,733 66,584 268,057 153,093 Net
(income) loss attributable to noncontrolling interests (79 )
185 (100 ) 502 Net income
attributable to Quintiles Transnational Holdings Inc. $ 92,654
$ 66,769 $ 267,957 $ 153,595
Earnings per share attributable to common shareholders: Basic $
0.73 $ 0.52 $ 2.08 $ 1.25 Diluted $ 0.71 $ 0.50 $ 2.03 $ 1.22
Weighted average common shares outstanding: Basic 127,462 128,923
128,780 122,467 Diluted 130,626 133,267 131,903 126,195
QUINTILES TRANSNATIONAL HOLDINGS INC. AND
SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in
thousands, except per share data)
September 30,
December 31, 2014 2013 (unaudited)
ASSETS Current assets: Cash and cash equivalents $ 645,034 $
778,143 Restricted cash 3,519 2,712 Trade accounts receivable and
unbilled services, net 1,032,553 924,205 Prepaid expenses 51,534
42,801 Deferred income taxes 94,175 92,115 Income taxes receivable
17,394 16,171 Other current assets and receivables 94,394
89,541 Total current assets 1,938,603
1,945,688 Property and equipment, net 190,863
199,578 Investments in debt, equity and other securities 33,723
40,349 Investments in and advances to unconsolidated affiliates
34,737 22,927 Goodwill 468,620 409,626 Other identifiable
intangibles, net 288,266 298,054 Deferred income taxes 31,278
32,864 Deposits and other assets 120,625
117,711 Total assets $ 3,106,715 $ 3,066,797
LIABILITIES AND SHAREHOLDERS’ DEFICIT Current
liabilities: Accounts payable and accrued expenses $ 830,388 $
861,805 Unearned income 526,000 538,585 Income taxes payable 19,219
35,778 Current portion of long-term debt and obligations held under
capital leases 20,681 10,433 Other current liabilities
30,492 35,646 Total current liabilities
1,426,780 1,482,247 Long-term debt and obligations held under
capital leases, less current portion 2,022,595 2,035,586 Deferred
income taxes 25,578 37,541 Other liabilities 167,994
178,908 Total liabilities 3,642,947
3,734,282 Commitments and contingencies Shareholders’
deficit: Common stock and additional paid-in capital, 300,000
shares authorized, $0.01 par value, 127,696 and 129,652 shares
issued and outstanding at September 30, 2014 and December 31, 2013,
respectively 368,010 478,144 Accumulated deficit (877,224 )
(1,145,181 ) Accumulated other comprehensive loss (27,045 )
(376 ) Deficit attributable to Quintiles Transnational
Holdings Inc.’s shareholders (536,259 ) (667,413 ) Deficit
attributable to noncontrolling interests 27
(72 ) Total shareholders’ deficit (536,232 ) (667,485
) Total liabilities and shareholders’ deficit $ 3,106,715 $
3,066,797
QUINTILES TRANSNATIONAL HOLDINGS
INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS (in thousands) (unaudited)
Nine Months
Ended September 30, 2014 2013 Operating
activities: Net income $ 268,057 $ 153,093 Adjustments to
reconcile net income to cash provided by operating activities:
Depreciation and amortization 89,113 76,950 Amortization of debt
issuance costs and discount 4,787 16,944 Share-based compensation
22,388 16,960 (Earnings) loss from unconsolidated affiliates (9,763
) 1,454 Gain on investments, net (4,806 ) (62 ) Benefit from
deferred income taxes (11,529 ) (15,883 ) Excess income tax
benefits from share-based award activities (12,802 ) (145 ) Changes
in operating assets and liabilities: Change in accounts receivable,
unbilled services and unearned income (118,721 ) (74,533 ) Change
in other operating assets and liabilities (50,927 )
3,133 Net cash provided by operating activities 175,797
177,911
Investing activities: Acquisition of property,
equipment and software (57,782 ) (73,940 ) Acquisition of
businesses, net of cash acquired (92,201 ) (144,970 ) Proceeds from
sale of equity securities 5,861 60 Investments in and advances to
unconsolidated affiliates, net of payments received (2,137 ) (5,944
) Other 332 802 Net cash used in
investing activities (145,927 ) (223,992 )
Financing
activities: Repayment of debt and principal payments on capital
lease obligations (6,729 ) (385,807 ) Issuance of common stock, net
of costs (105 ) 489,560 Stock issued under employee stock purchase
and option plans 23,201 364 Repurchase of common stock (165,131 ) —
Payroll taxes remitted on repurchase of stock options (8,415 ) —
Excess income tax benefits from share-based award activities
12,802 145 Net cash (used in) provided by
financing activities (144,377 ) 104,262 Effect of foreign currency
exchange rate changes on cash (18,602 ) (16,199 )
(Decrease) increase in cash and cash equivalents (133,109 ) 41,982
Cash and cash equivalents at beginning of period 778,143
567,728 Cash and cash equivalents at end of
period $ 645,034 $ 609,710
QUINTILES
TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES CONSOLIDATED
SEGMENT OPERATIONS (in thousands) (unaudited)
Three
Months Ended September 30, Nine Months Ended September
30, 2014 2013 2014 2013 Service
revenues Product Development $ 771,361 $ 714,244 $ 2,323,376 $
2,144,721 Integrated Healthcare Services 289,652
218,483 778,401 659,679
Total service revenues 1,061,013 932,727 3,101,777 2,804,400
Costs of revenue, service costs Product Development 458,731
426,094 1,374,492 1,296,996 Integrated Healthcare Services
232,320 174,600 634,795
532,473 Total costs of revenue, service costs 691,051
600,694 2,009,287 1,829,469
Selling, general and
administrative Product Development 154,460 147,534 471,697
438,341 Integrated Healthcare Services 37,447 32,221 103,069 96,792
General corporate and unallocated 27,120
19,818 82,517 92,580 Total
selling, general and administrative 219,027 199,573 657,283 627,713
Income from operations Product Development 158,170
140,616 477,187 409,384 Integrated Healthcare Services 19,885
11,662 40,537 30,414 General corporate and unallocated (27,120 )
(19,818 ) (82,517 ) (92,580 ) Restructuring costs (1,793 )
(7,201 ) (3,749 ) (11,897 ) Total income from
operations $ 149,142 $ 125,259 $ 431,458 $
335,321
QUINTILES TRANSNATIONAL HOLDINGS
INC. AND SUBSIDIARIES RECONCILIATION OF GAAP TO NON-GAAP
MEASURES (in thousands, except per share data) (unaudited)
Three Months Ended September 30, Nine Months Ended
September 30, 2014 2013 2014 2013
Adjusted
EBITDA
Net income attributable to Quintiles Transnational Holdings Inc. $
92,654 $ 66,769 $ 267,957 $ 153,595 Net income (loss) attributable
to noncontrolling interests 79 (185 ) 100 (502 ) Interest expense,
net 24,448 27,637 71,701 94,326 Income tax expense 41,260 27,459
111,049 68,407 Depreciation and amortization 30,180 27,324 89,113
76,950 Restructuring costs 1,793 7,201 3,749 11,897 Management fees
(1) — — — 27,694 Loss on extinguishment of debt — — — 16,543 Other
expense (income), net (7,776 ) 3,224 (9,564 ) 1,378 Equity in
(earnings) losses from unconsolidated affiliates (1,523 )
355 (9,785 ) 1,574 Adjusted
EBITDA $ 181,115 $ 159,784 $ 524,320 $ 451,862
Adjusted Income from
Operations
Income from operations, as reported $ 149,142 $ 125,259 $ 431,458 $
335,321 Restructuring costs 1,793 7,201 3,749 11,897 Management
fees (1) — — —
27,694 Adjusted income from operations $ 150,935 $
132,460 $ 435,207 $ 374,912
Adjusted Net
Income
Net income attributable to Quintiles Transnational Holdings Inc. $
92,654 $ 66,769 $ 267,957 $ 153,595 Restructuring costs 1,793 7,201
3,749 11,897 Management fees (1) — — — 27,694 Loss on
extinguishment of debt — — — 16,543 Adjustment to estimated
contingent consideration (2) (8,757 ) (1,224 ) (8,839 ) (1,455 )
Tax effect of adjustments (3) (705 ) (2,032 ) (1,298 ) (20,303 )
Other income tax adjustments (4) — —
— 3,057 Adjusted net income $ 84,985
$ 70,714 $ 261,569 $ 191,028
Diluted weighted average common shares outstanding 130,626 133,267
131,903 126,195 Diluted adjusted earnings per share $ 0.65 $ 0.53 $
1.98 $ 1.51 (1) Management fees were previously paid to
affiliates of certain of the Company’s shareholders pursuant to a
management agreement. The nine month period ended September 30,
2013 includes a $25.0 million fee paid in connection with the
termination of the management agreement. (2) During the
third quarter of 2014, the Company began excluding changes from
adjustments to estimated contingent consideration from business
combinations from adjusted net income and diluted adjusted earnings
per share. Consistent with the other adjustments to adjusted net
income and diluted adjusted net income per share, management
believes that changes to the estimated value of contingent
consideration are not indicative of its core operating results as
the fluctuations from period-to-period do not necessarily
correspond to changes in the core operations of the business. There
was no contingent consideration impact to EPS during three months
ended March 31, 2014 or June 30, 2014. (3) The tax effect of
adjustments was based on the income tax rate of the respective
transactions, which was 38.5%, with the exception of i)
restructuring costs which were tax effected at 39.3% and 27.5%
during the three months ended September 30, 2014 and 2013,
respectively, and 34.6% and 27.5% during the nine months ended
September 30, 2014 and 2013, respectively and ii) contingent
consideration which is not tax effected as it represents a
permanent difference between book and tax income. (4) Other
income tax adjustments remove the impact of certain discrete
adjustments on the Company’s income tax expense in the nine month
period in 2013. The Company’s effective income tax rate in the 2013
periods was impacted by the Company’s change in assertion regarding
the undistributed earnings of most of the Company’s foreign
subsidiaries, which are now considered to be indefinitely
reinvested outside of the United States. As a result of the
assertion change, in the second quarter of 2013, the Company
recorded an $8.1 million discrete income tax benefit to reverse the
deferred income tax liability previously recorded on undistributed
foreign earnings. In addition, in the second quarter of 2013, the
Company settled certain intercompany notes that had previously been
considered long term investments, which resulted in an $11.2
million discrete income tax expense.
QUINTILES
TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES RECONCILIATION
OF GAAP TO NON-GAAP MEASURES (Continued)
(in thousands, except per share data)
(unaudited)
Three Months Ended Year Ended
March 31, June 30, September 30, December
31, December 31, 2013 2013 2013
2013 2013
Adjusted Net
Income
Net income attributable to Quintiles Transnational Holdings Inc. $
48,309 $ 38,517 $ 66,769 $ 72,996 $ 226,591
Restructuring costs 1,859 2,837 7,201 2,174 14,071 Management fees
(1) 1,334 26,360 — — 27,694 Loss on extinguishment of debt — 16,543
— 3,288 19,831 Adjustment to estimated contingent consideration (2)
(231 ) — (1,224 ) (3,455 ) (4,910 ) Tax effect of adjustments (3)
(1,183 ) (17,088 ) (2,032 ) (2,001 ) (22,304 ) Other income tax
adjustments (4) 7,301 (4,244 )
— — 3,057 Adjusted
net income $ 57,389 $ 62,925 $ 70,714
$ 73,002 $ 264,030 Diluted
weighted average common shares outstanding 118,740 126,578 133,267
132,861 127,862 Diluted adjusted earnings per share $ 0.48 $ 0.50 $
0.53 $ 0.55 $ 2.06 (1) Management fees were previously paid
to affiliates of certain of the Company’s shareholders pursuant to
a management agreement. The quarter ended June 30, 2013 and the
year ended December 31, 2013 include a $25.0 million fee paid in
connection with the termination of the management agreement.
(2) During the third quarter of 2014, the Company began excluding
changes from adjustments to estimated contingent consideration from
business combinations from adjusted net income and diluted adjusted
earnings per share. Consistent with the other adjustments to
adjusted net income and diluted adjusted net income per share,
management believes that changes to the estimated value of
contingent consideration are not indicative of its core operating
results as the fluctuations from period-to-period do not
necessarily correspond to changes in the core operations of the
business. To conform to the current period presentation, all the
periods for fiscal year 2013 in the table above reflect the
inclusion of this adjustment. (3) The tax effect of
adjustments was based on the income tax rate of the respective
transactions, which was 38.5%, with the exception of i)
restructuring costs which were tax effected at 36.0%, 20.1%, 27.5%,
32.3% and 28.2% during the three months ended March 31, 2013, June
30, 2013, September 30, 2013, December 31, 2013 and for the year
ended December 31, 2013, respectively and ii) contingent
consideration which is not tax effected as it represents a
permanent difference between book and tax income. (4) Other
income tax adjustments remove the impact of certain discrete
adjustments on the Company’s income tax expense in 2013. The
Company’s effective income tax rate in the 2013 periods was
impacted by the Company’s change in assertion regarding the
undistributed earnings of most of the Company’s foreign
subsidiaries, which are now considered to be indefinitely
reinvested outside of the United States. As a result of the
assertion change, in the second quarter of 2013, the Company
recorded an $8.1 million discrete income tax benefit to reverse the
deferred income tax liability previously recorded on undistributed
foreign earnings. In addition, in the second quarter of 2013, the
Company settled certain intercompany notes that had previously been
considered long term investments, which resulted in an $11.2
million discrete income tax expense.
QUINTILES
TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES RECONCILIATION
OF GAAP TO NON-GAAP MEASURES (Continued) (in millions, except
per share data) (unaudited)
Reconciliation of GAAP to
Non-GAAP Full Year 2014 Guidance Adjusted Net Income
Diluted Adjusted Earnings Per Share Low High
Low High Net income attributable to Quintiles and
diluted earnings per share $ 344 $ 354 $ 2.61 $ 2.68 Restructuring
costs 13 13 0.10 0.10 Adjustment to estimated contingent
consideration (9 ) (9 ) (0.07 ) (0.07 ) Tax effect of adjustments
(1) (4 ) (4 ) (0.03 ) (0.03 ) Adjusted
net income and diluted adjusted earnings per share $ 344 $
354 $ 2.61 $ 2.68 (1) Restructuring
costs are tax effected at approximately 30.0%. Contingent
consideration is not tax effected as it represents a permanent
difference between book and tax income.
QuintilesPhil Bridges, Media Relations
(phil.bridges@quintiles.com)919-998-1653 (office), 919-457-6347
(mobile)orKarl Deonanan, Investor Relations
(InvestorRelations@quintiles.com)919-998-2789
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jul 2023 to Jul 2024